GAL and neoplasm: As described in the section on anti-Gal-mediated conversion of human tumors into autologous anti-tumor vaccines, in situ immunocomplexing of anti-Gal with tumor cells presenting α-gal epitopes can result in effective targeting of the tumor cells to APC due to the Fc tail of anti-Gal binding to Fc receptors on macrophages and dendritic cells.